Tongkat Ali, Fadogia agrestis and Cistanche tubulosa are often grouped together in men’s performance conversations. That can make them sound interchangeable. They are not.
They come from different plants, use different label conventions and sit at very different points on the evidence ladder. A responsible comparison should separate what the label confirms, what human research has studied and what remains uncertain.
At-a-glance comparison
| Ingredient | VitaPrime label specification | Human evidence position | Main uncertainty |
|---|---|---|---|
|
Tongkat Ali Eurycoma longifolia |
500 mg extract per capsule; standardised to 2% eurycomanone | Clinical trials and a meta-analysis exist, but populations, extracts and study quality vary | Results from one extract cannot automatically be transferred to every product |
| Fadogia agrestis | 500 mg of 20:1 extract per capsule | No established human clinical evidence located; published work is primarily animal or laboratory research | Human effectiveness, appropriate dosing and long-term safety remain uncertain |
| Cistanche tubulosa | 400 mg per serving; 60% total phenylethanoid glycosides, including 20% echinacoside and 8% acteoside | Some human studies exist, including combination-product research; the evidence is not equivalent to proof for every single-ingredient product or outcome | Combination trials cannot isolate Cistanche’s independent contribution |
Tongkat Ali: the strongest human evidence of the three, with limits
Tongkat Ali is the common name for Eurycoma longifolia. VitaPrime Elite specifies 500 mg of extract per capsule and standardisation to 2% eurycomanone. Standardisation provides a measurable reference point for batch-to-batch comparison; it does not by itself prove a clinical result.
A 2022 systematic review and meta-analysis evaluated clinical trials examining total testosterone in men. The pooled findings suggested a possible effect, particularly in some men with lower testosterone, but the authors also highlighted the need for more research. Study populations, durations, doses and extracts differed.
Practical reading: Tongkat Ali has a more developed human research base than Fadogia, but “studied ingredient” is not the same as “this exact product is clinically proven”.
Fadogia agrestis: animal findings are not human proof
VitaPrime Elite lists 500 mg of a 20:1 Fadogia agrestis extract. A 20:1 ratio describes the relationship between starting plant material and finished native extract under a particular extraction process. It does not tell you that the product is twenty times more effective, and it is not a standardised percentage of a clinically validated active compound.
The frequently cited testosterone and sexual-behaviour research was conducted in male rats, not men. Other animal research has reported adverse testicular changes and markers consistent with liver and kidney cellular injury. Animal findings do not establish the same benefit or harm in humans—but the combination of no established human efficacy trials and preclinical safety signals is a material evidence limitation that buyers deserve to know.
Practical reading: Fadogia is the most uncertain of these three ingredients. Avoid treating online anecdotes as clinical evidence.
Cistanche tubulosa: detailed marker specification, emerging human research
VitaPrime Elite specifies a 400 mg serving standardised to 60% total phenylethanoid glycosides, including 20% echinacoside and 8% acteoside. This is more informative than a raw milligram number alone because it identifies measured constituent classes.
Human studies have examined Cistanche-containing preparations for selected outcomes. Some trials use a combination of Cistanche and Ginkgo extracts, which means any result belongs to the tested combination and cannot be confidently attributed to Cistanche alone. Research on one formulation also does not validate unrelated claims about hormones, strength, libido or longevity.
Practical reading: the label offers useful constituent detail, while the clinical evidence remains outcome- and formulation-specific.
What about taking all three together?
A stack can be convenient, but convenience is not proof of synergy. We did not identify clinical trials showing that Tongkat Ali, Fadogia and Cistanche together produce better outcomes than the individual ingredients. Each product should therefore be assessed on its own label, evidence and safety profile.
If you use more than one supplement, introduce changes cautiously, follow the product label, and discuss the combination with a qualified health professional—especially if you take medication, have a liver, kidney, cardiovascular, endocrine or mental-health condition, or are trying to conceive.
Which comparison matters most?
- For evidence maturity: Tongkat Ali currently has the clearest human research base of the three, although limitations remain.
- For marker transparency: Tongkat Ali and Cistanche provide standardised constituent information on the VitaPrime labels.
- For uncertainty: Fadogia requires the greatest caution because human evidence is not established and animal safety signals exist.
- For any product: identity testing, contaminant testing, accurate labelling and interaction screening matter as much as headline milligrams.
Compare the exact labels
Read the full ingredient specifications, capsule counts, directions and warnings before deciding whether any product fits your situation.
Sources and evidence notes
- Tongkat Ali systematic review and meta-analysis of clinical trials
- Fadogia agrestis animal study on testosterone and sexual behaviour
- Fadogia agrestis animal study reporting adverse testicular effects
- Fadogia agrestis animal study examining liver and kidney cellular toxicity
- Randomised trial of a Cistanche and Ginkgo combination